PURPOSE: Several observations suggest the presence of HIV-suppressive factors in the fluid phase of blood. Alpha-1-antitrypsin (AAT), the most abundant serine protease inhibitor in the circulation, has potent anti-HIV activity in vitro, and may function as an endogenous HIV suppressor. Therefore, we assessed serum AAT concentrations for association with HIV infection. METHODS: In this cross-sectional study, serum AAT concentrations were measured in 66 persons with HIV infection and in 45 healthy persons (Controls). In the HIV-infected group, antiretroviral therapy (ART) use was assessed and CD4+ T cell levels and plasma HIV RNA were quantified. RESULTS: Median AAT concentration was significantly lower in the HIV-infected group (1.64 mg/mL) in comparison with Controls (1.94 mg/mL; p=0.001). AAT reduction was most pronounced in the HIV-infected subgroup with CD4+ T cell levels > 200 cells/µL in comparison with Controls (p < 0.01). Serum AAT concentrations < 1.0 mg/mL are clinically significant, and concentrations below this level were identified in 4.5% of the HIV-infected group and in no Control subjects. No association between AAT levels and viral load or use of ART was observed in HIV-infected subjects. CONCLUSION: The association between reduced serum AAT concentration and HIV infection is consistent with a role for AAT as an endogenous HIV suppressor.
PURPOSE: Several observations suggest the presence of HIV-suppressive factors in the fluid phase of blood. Alpha-1-antitrypsin (AAT), the most abundant serine protease inhibitor in the circulation, has potent anti-HIV activity in vitro, and may function as an endogenous HIV suppressor. Therefore, we assessed serum AAT concentrations for association with HIV infection. METHODS: In this cross-sectional study, serum AAT concentrations were measured in 66 persons with HIV infection and in 45 healthy persons (Controls). In the HIV-infected group, antiretroviral therapy (ART) use was assessed and CD4+ T cell levels and plasma HIV RNA were quantified. RESULTS: Median AAT concentration was significantly lower in the HIV-infected group (1.64 mg/mL) in comparison with Controls (1.94 mg/mL; p=0.001). AAT reduction was most pronounced in the HIV-infected subgroup with CD4+ T cell levels > 200 cells/µL in comparison with Controls (p < 0.01). Serum AAT concentrations < 1.0 mg/mL are clinically significant, and concentrations below this level were identified in 4.5% of the HIV-infected group and in no Control subjects. No association between AAT levels and viral load or use of ART was observed in HIV-infected subjects. CONCLUSION: The association between reduced serum AAT concentration and HIV infection is consistent with a role for AAT as an endogenous HIV suppressor.
Authors: Engi F Attia; Kathleen M Akgün; Cherry Wongtrakool; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; David Rimland; Sheldon T Brown; Guy W Soo Hoo; Joon Kim; Patty J Lee; Lynn M Schnapp; Amir Sharafkhaneh; Amy C Justice; Kristina Crothers Journal: Chest Date: 2014-12 Impact factor: 9.410
Authors: Xueyuan Zhou; Zhu Liu; Jun Zhang; Joseph W Adelsberger; Jun Yang; Gregory F Burton Journal: BMC Microbiol Date: 2016-07-29 Impact factor: 3.605
Authors: Xiyuan Bai; Joseph Hippensteel; Alida Leavitt; James P Maloney; David Beckham; Cindy Garcia; Qing Li; Brian M Freed; Diane Ordway; Robert A Sandhaus; Edward D Chan Journal: Med Hypotheses Date: 2020-11-12 Impact factor: 1.538
Authors: Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn Journal: PLoS One Date: 2012-11-02 Impact factor: 3.240